The origin of activity differences between stereoisomers of anticancer platinum(II) complexes chelated with chiral diamine ligands has been almost exclusively explained by diastereoselective interactions with DNA. Although this model has been widely accepted in vitro and in vivo experiments showed some conflicting results, leading to the conclusion that other biomolecules might be responsible for this stereoselectivity as well. These compounds, called bionucleophiles, are in most instances amino acids or proteins present in biological fluids. As these chiral molecules are very reactive towards the platinum complexes, they may contribute to stereoselectivity, but also to resistance and toxicity. This review gives a general survey of chiral platinum(II) complexes and their interactions with DNA. The bionucleophiles which have been identified and the consequences of their reaction with platinum(II) complexes are discussed. Analytical techniques used to investigate interactions between established and potential chiral platinum drugs and bionucleophiles are presented.
INTRODUCTION
It has been established for about fifty years that stereochemistry is fundamental in pharmacology [1] [2] [3] [4] [5] [6] . Indeed, the influence of relative and absolute configuration on absorption, distribution, target binding, and elimination of therapeutic molecules is a critical point to be studied before approval for medical applications. For this reason, public health organizations emphasize the analysis of each stereoisomer, to detect possible drawbacks of the drug candidates (for instance, see FDA's guidelines : « FDA's policy statement for the development of new stereoisomeric drugs », published in 1992).
Platinum anticancer drugs have been somewhat kept aside from this problem although three out of six complexes approved for therapy have a chiral structure (3, 5 and 6) ( Fig. 1) . The most wellknown is oxaliplatin (3) . This drug is the (1R,2R) enantiomer of the 1,2-diaminocyclohexane (DACH) oxalatoplatinum(II) complex and has been worldwide approved for the treatment of metastatic colorectal carcinoma [7, 8] . Both other complexes (5 and 6) have only limited approval. SKI 2053 R (or heptaplatin (5) ) has been used in South-Korea since the middle 1990's for the treatment of gastric cancer but there is little information about its stereochemical related properties in vitro and in vivo [9] . Lobaplatin (6) is a mixture of trans-isomers. Some compounds are currently tested or have been used in clinical trials (Fig. 2) . They derive from oxaliplatin and the DACH group acts as chelating agent. Complex (7) , called TRK-710, differs from oxaliplatin by its leaving group and is also accompagnied by a counter-ion since it bears a positive charge (Fig.  2) . Compound (8) , called ormaplatin (or tetraplatin), which belongs to the platinum(IV) complex family, is a mixture of trans isomers of DACH and was a promising candidate for anticancer therapy but has been abandoned because of its high neurotoxicity in phase I clinical trials [10] . Some papers report cytotoxicity studies on tetraplatin stereoisomers, showing the same results obtained with oxaliplatin isomers: RR-8 > SS-8 and RS-8 in the majority of the cell lines used [11] . Other studies have compared the racemate of 8 with SS-8 [12] and RR-8 [13] . However, curiously, most authors *Address correspondence to this author at the Institut de Pharmacie, Université Libre de Bruxelles CP205/5, Campus Plaine, 1050, Brussels, Belgium; Tel: 003226505235; Fax: 003226505249; E-mail: dufrasne@ulb.ac.be have not been interested in the use of pure optical isomers of compound (8) and analogues, although trans-R,R-diaminocyclohexane is easily accessible by commercial suppliers or can be isolated via the respective tartrate salt from the racemate.
The origin of the stereoselective activity of chiral platinum complexes has been attributed, as for « classical » drugs, to discriminations determined by the target, already identified as being the DNA. This was observed for the first time by Kidani for complexes with DACH ligands and their derivatives [14] [15] [16] . Indeed, as DNA has a chiral structure, this theory was the most relevant for the understanding of stereoselection. Many studies, using molecular modelling, spectroscopic techniques and crystallography, have shown energetically favourable interactions between chiral ligands of platinum complexes stereoisomers and DNA structure or small nucleotides [17] [18] [19] [20] [21] [22] . The first class of compounds used to investigate the relations between spatial configuration of the ligand and the ability of the complexes to form efficient adducts with DNA was the DACH series [8, [23] [24] [25] . This special feature arises from the fact that each DACH stereoisomer has a particularly stable bulk structure with a nearly planar shape for (RR) and (SS)-(DACH) dichloroplatinum(II) (structure A, Scheme 1) and a L-shaped molecule for the (RS) stereosiomer (structure B, Scheme 1). As a consequence of these observations, when the RS stereoisomer forms an adduct with DNA, significant steric hindrance is expected, resulting in a slower binding of the complexes to DNA as well as a different recognition and processing of the formed adducts. This theory is confirmed by numerous cytotoxicity tests on DACH and their structural analogues which have, in most cases, shown the same order of activity (RR SS > RS).
Despite these evidences, also some controversial results were obtained with chiral platinum complexes. Sometimes, when small modifications are made in the structure of chemically related compounds (for instance: change in substitution pattern of an aromatic ring or an alkyl chain) or in the conditions used to test the complexes (for instance: change in cell lines, change from in vitro to in vivo test), a reversal of the stereoselectivity order can be detected. These observations have been made with diastereoisomers and even with enantiomers. It appears from these findings that other factors than DNA structure alone may influence stereoselectivity. Consequently, it is crucial to understand, how the biological components of the human body will interact with different isomers of platinum anticancer drugs and to identify them. This analysis could shed more light on the mechanism of action of chiral platinum complexes and would help to design novel analogues with improved anticancer properties and a more favourable pharmacological profile.
Cl Cl Fig. (2) . Other important platinum complexes derived from oxaliplatin: TRK-710 (7) and ormaplatin (8) .
Scheme (1). Three-dimensional representations of (trans-1R,2R-diaminocyclohexane) dichloroplatinum(II) (A) and (cis-1R,2S-diaminocyclohexane) dichloroplatinum(II) (B) (3D-structures performed with PC-MODEL ® 7.0, Serena Software) .
DISTRIBUTION AND MODE OF ACTION OF ANTICAN-CER PLATINUM(II) COMPLEXES
Metal complexes show a significantly different pharmacological behaviour due to the metal centre. Platinum compounds are in principle able to react with all nucleophiles present in blood and cells [26] . The different steps involved in the anticancer action of platinum(II) complexes are quite well understood and described (see Scheme 2). All approved platinum complexes used in cancer chemotherapy are injected intravenously and, consequently, the behaviour of such complexes in the gastrointestinal tract is not well investigated. Recently, some attempts were made to develop orally active compounds. Good examples of these "per os" complexes are satraplatin (JM216, a platinum(IV) complex in phase III clinical trials), LA-12 (an aminoadamantane derivative of satraplatin, which has finished clinical phase I) [27] , AMD473 (JM473) and some derivatives of oxaliplatin presenting more lipophilic leaving groups (C5-OHP-C1) [25, 28] . In this context it has to be mentioned that oral absorption is based on crossing the intestinal wall by simple diffusion mechanisms which are mainly dependent on the partition coefficients of the compounds between water and cell membranes. In addition, such types of complexes have to be stable enough under the conditions in the gastro-intestinal tract.
When injected, the complexes can bind to circulating blood proteins, especially to albumin and, to a lesser extent, to haemoglobin and -globulins. For example, the fraction of cisplatin, oxaliplatin and carboplatin bound to plasma proteins is, respectively, 90 %, 85 % and ~ 37% [29] . These protein bound complexes are believed to be devoid of anticancer activity and lost for therapy. The proteins, which can react with platinum and other heavy metals, are essential to detoxify the organism. In cytosol, metallothioneins and glutathione have the same effect and « deactivate » metal drugs (biological cytoprotective agents). For this reason, interaction of platinum complexes with proteins and other sulfurcontaining biomolecules is one of the critical points to be studied in conjunction with testing the platinum drug candidates in cellular or biological systems. Platinum complexes will be chemically modified in extra-and intra cellular body fluids but not in the same way as « organic drugs ». They are transformed by a non-enzymatic reaction, a stepwise hydrolysis (also called « aquation ») of the leaving groups ending up in an activated form in which the complex has one or two coordinated water molecules bound to the platinum core. Thanks to the positively charged hydrolysis products, these newly generated species are strong electrophiles which are now able to efficiently react with anions or electron-rich parts of biological components. If the complex can not reach the cancer cells, it is excreted mainly by the kidney and poorly in faeces. The renal clearance of cisplatin and oxaliplatin may be considered as slow in comparison to the large majority of drugs with 50 % of the dose eliminated by the kidney after only 5 days [30] . In the case of cisplatin, high platinum concentrations in the kidneys are accompanied by dose-limiting severe side-effects due to destruction of the renal tissues.
Only a small fraction of the drug reaches the cancer cells and has still to cross the cell and nucleus membranes to react with the final target: DNA. The precise mechanism of cell penetration has Fig. (1) . Platinum complexes approved for antitumor therapy: cisplatin (1), carboplatin (2), oxaliplatin (3), nedaplatin (4), SKI 2053 R (5) and Lobaplatin (6) . not yet been identified. It is generally well accepted that the complexes pass the cell wall by passive diffusion. Indeed the phenomenon can not be saturated or inhibited by structural analogues [26] . However, some clues for a transport suggest the implication of a metal transport protein: copper transporter 1 (CTR1) [31] . This protein seems to be involved in the uptake of the complexes as well as in their efflux [32] [33] [34] . Strictly speaking, this does not mean that CTR1 is the influx reporter for platinum complexes, but a reduction of cellular uptake in CTR1 knockout Saccharomyces cerevisiae strains of copper (16-fold) and cisplatin (8-fold) measured at 1 h suggests a certain role of CTR1 as one possible route of cisplatin influx.
When the activated platinum complex binds to DNA, several well identified phenomena take place which finally trigger apoptosis (programmed cell death). These include: i. modification (denaturation) of the DNA structure, ii. binding of specialized proteins (maybe the most important are High Mobility Group proteins or HMG) which recognize damaged DNA thereby shielding such regions from repair. Contrary, other proteins will restore the integrity of DNA by repair of the injured zones, leading in this way to resistance (Nucleoside Excision Repair or NER).
After analysis of the described mechanisms and reactions of the platinum complexes in blood and cells, it is obvious that, at each step, the stereochemistry of the diamine ligand has a critical role to play in anticancer activity. Stereoisomers may have different reaction rates with biological compounds (proteins, DNA, aminoacids,…) or the stability of these reaction products may be different according to their geometry.
INFLUENCE OF THE LIGAND'S STEREOCHEMISTRY ON PHARMACOKINETICS AND ACTIVITY OF PLATI-NUM(II) ANTICANCER COMPLEXES 3.1. Platinum(II) Complexes Showing Stereoselective Biological Properties
Besides the above-mentioned chiral complexes, a large variety of such compounds has been synthesized and tested in vitro or in vivo. Some of them have shown significant stereoselectivity in their cytotoxicity and/or toxicity ( Fig. 3 and Table 1 ). It has been decided to analyze separately compounds with different size of diazaplatina cycles. Complexes have been divided into three groups: the compounds of which have, respectively, 5, 6 or 7 atoms in the chelate ring. Among them, only 5-membered cycle complexes provide useful results for analysis because of the variety of compounds tested. If structurally related complexes are compared to each other, shared features are seldom observed for the most active isomers. For instance, complexes R-(9c), S-(15), S-(18a) and S-(18b), which differ by their substituents in position 1 of the carbon chain, show the same absolute configuration and are also the most active compounds within their series. However, R-9a and R-10 have an absolute configuration opposed to that of the above-mentioned molecules. In another class of compounds with two chiral centres and one or two phenyl ring(s) as substituents, surprising results have been obtained. Indeed, the SS enantiomers of diphenylethanediamine complexes (19b-d) are always the most cytotoxic, independently of the substitution pattern on the aromatic rings. Nevertheless, when one phenyl ring is replaced by an alkyl chain, the selectivity between enantiomers changes following the type of substituent on Scheme (2). General pharmacokinetics of anticancer platinum(II) complexes (biological compounds which bind to platinum and reduce its activity are in italic or marked with dashed arrows, transport systems are underlined). Note that the aquation step may happen predominantly in cytoplasm, depending on the type of leaving group. the phenyl group and the type of alkyl chain, with a small advantage for RR enantiomers. These results definitively show that the relation between stereochemistry of the diamine ligand and the configuration of DNA is not the only way to explain differences in cytotoxicity of enantiomers.
In addition to these observations with parent complexes, particularly amazing results, which will be discussed in detail in section 3.3, have been obtained with compounds subjected to a small modification in substitution pattern or in leaving groups, or using different experimental conditions ( Table 2 and Fig. 3) . The large majority of fundamental studies about mechanism of action of platinum complexes point out DNA as the most important target for these drugs [26, 58] , although interactions with other biological compounds, as proteins actin and filamin, have also been reported recently to be involved [59] . Since chiral structure and absolute configuration of DNA are basically the same in all living organism cells, including cancer cells, other factors must have a significant impact on the cytotoxicity of platinum complex stereoisomers.
Identified Factors Affecting Cytotoxic Activity of Anticancer Platinum(II) Complexes and their Relation to Stereochemistry
The most evident and most studied factor correlating the stereoselectivity with the cytotoxic properties of anticancer platinum LG
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LG complexes is the target itself. Very soon, DNA has been identified as the origin of anticancer activity of platinum(II) complexes [60] . Particularly well adapted techniques have been used to demonstrate these interactions and they also showed the way in which the structure of DNA could be modified by platinum coordination. X-ray crystal diffraction of complex-oligonucleotide adducts have highlighted large changes into nucleic acid conformation (see Scheme 3). The Lippard's group from the MIT has shown very obviously on a double stranded DNA dodecamer that binding of cisplatin induced remarkable modifications of orientation and shape of DNA, with a bending of the structure by ± 20°. Other characteristics of the adducts led the authors to the conclusion that the DNA has shifted from a B-form into an A-form [61] . These findings were confirmed later by 2D NOESY 1 H-NMR experiments on the same type of adducts [62] . Nuclear magnetic resonance is especially well adapted to solution structures of platinum adducts with small DNA duplexes, giving an accurate representation under biologically relevant conditions. Such experiments were very useful in order to determine the mechanism by which enantio-or diastereoisomer differentiation occurs in vitro and vivo. Indeed, at this stage, two mechanisms could be involved into induction of stereoselectivity (see scheme 4). The first of them occurs during the initial binding phase of the complex to the DNA and was directly referred to the diastereoisomeric complexes with DACH ligands [16] . It finds its origin in unfavourable bulky interactions between DNA and the ligands. In the case of cis-R,S-DACH platinum complexes, the cyclohexane ring adopts a nearly perpendicular arrangement with respect to the N 2 PtO 2 plane. The second one takes place during the bending of the DNA and is a result of the later findings about twisting in DNA structure also leading to stereochemical discriminations. As a matter of fact, it has been largely demonstrated that this distorted shape of double stranded DNA is specifically recognized in the case of oxaliplatin type complexes by HMGB proteins, which shield this bended part of the DNA from repair and thereby trigger apoptosis [58] .
To support these proposals, various experiments have been conducted with chiral platinum(II) complexes. The most frequently studied class of compounds consequently included the DACH complexes and close analogues thereof. Earlier studies investigating the reactions with dinucleotides (GpG) have confirmed that the activity order found in vitro is strongly dependent on the degree of the overall nucleic acid structural change: the most important differences are observed between RR-11a/SS-11a and RS-11a, the smallest between RR-11a and SS-11a [18] . Later, Boudny and coworkers have shown on larger nucleotide fragments that the critical structure modification which could explain enantiomeric differences is the bending of the structure [64] . Global structural changes obtained with RR-11a are practically the same as those obtained with cisplatin, while the torsion induced by SS-11a binding is less effective. On the other hand, the bending caused by RS-11a, the least active isomer, is larger than the one obtained with its diastereoisomeic counterparts. So, these results demonstrate the involvement of the ligand's stereochemistry into the extent of denaturation of DNA but fail to prove that the larger DNA distortions lead to the higher activities. Later, it has been demonstrated that this is the bending angle which is the critical factor explaining the cytotoxic power of these compounds. Other surprising observations have been made by calculating the ability of platinum complexes to damage DNA. In this experiment, Murray and coworkers have measured damaging efficacy of DNA in the following order: cisplatin > SS-11a > RR-11a [65] . On the other hand, in a merely theoretical model, molecular modelling studies have been carried out on adducts of RR-11a, SS-11a and RS-11a with two guanines [66] . Calculated energies of the products were consistent with stereoselective cytotoxicities as observed in some cancer cell lines. Another interesting experiment has been performed on R-and S-15 by Morikawa and coworkers [67] . Using UV spectra and circular dichroism of DNA following exposition to each enantiomer, they revealed that the structural changes are larger for the most active enantiomer S-15. To be exhaustive, it must be noted that some works, which aimed to prove diastereoselective interactions of chiral platinum complexes deriving from DACH ligands with DNA dramatically failed although they used the same methods [68] [69] .
In addition to these findings on clinically important complexes, other chiral compounds have been studied from a fundamental point of view. Complexes (9d) and (17) have been used to investigate the dynamic behaviour of guanine residues and derivatives after platinum binding [22, 70, 71] . In the first place, these compounds have been tested only with guanines or their derivatives and not with nucleotides, providing only few information about their real effect on DNA conformation. Nevertheless, these experiments clearly showed that chirality of the ligand may influence DNA bases orientation. Later on, adduct formation of SS-and RR-9d towards DNA fragments or dinucleotides has been evaluated [72] . The authors clearly demonstrate that a DNA destabilization is more important for SS-9d than in the case of the other enantiomer. Surprisingly, the bending angle after the binding of SS-9d was smaller in comparison to its enantiomeric counterpart. These observations are in agreement with cytotoxicity tests performed with structurally related complexes (19b-19d) (phenyl moieties instead of methyl groups), for which the most active isomer is always the SS one. Furthermore, recent investigations have been performed about the interactions between proteins which specifically recognize (HMG) and repair (NER) DNA sites bound to platinum complexes [73] . It has been shown that RR-9d causes lesions, which are more easily recognized by HMG proteins and, in addition, which are less sensitive to NER action. These observations pointed out the crucial role of protein interactions with binding sites of platinum complexes at DNA. To complete this overview of outstanding facts, a very recent report, using gel electrophoresis on small DNA fragments has demonstrated that HMG proteins bind differently to DNA after exposition to R-and S-16a [74] . This is explainable by different bending angles attributed to the respective configuration of the ligands.
Conflicting Results
As described above, numerous experimental proofs have been given to explain that DNA is the chiral selector yielding stereoselectivity in anticancer activity of stereoisomers of platinum complexes. Despite these observations, some results arise as exceptions to this rule (see Table 2 ). They can be divided into six categories in which the order of activity varies significantly following: i. in vitro and in vivo testing (entry 1), ii. cancer cell lines (entries 2 to 6), iii. theoretical predictions and experimental results (entry 7), iv. experimental conditions and/or other compounds added during the cytotoxicity evaluation (entry 8), v. substitution pattern of the ligands or changes in leaving groups (entries 9 to 13), vi. biochemical cancer cell characteristics (entry 14).
The outstanding feature from these observations is that other factors must be taken into account to explain and/or to predict stereoselectivity before designing new chiral anticancer platinum complexes. It is obvious that these factors include biological molecules present in extracellular and/or intracellular fluids, but also proteins or receptors located on the cell membrane. Indications for this assertion consist in numerous differences observed when miscellaneous cancer cell lines have been used and, still more obviously, when in vitro or in vivo experiments are compared. It has already been mentioned that DNA is structurally equivalent in all cells, cancerous or not, even if the nucleoside composition is different. As platinum complexes bind preferably to GG and, to a lesser extent, to AG sequences, DNA sites particularly rich in guanine and adenine are more sensitive to reaction with platinum. Very few attempts have been made to design new chiral complexes with the expected enantiospecific activity on the basis of molecular modelling or docking experiments. In general, quantitative structureactivity relationship (QSAR) data are nearly not available in this field of research due to the problems described above. One step in this direction was presented by Hambley [20] ; the group of Osella has more recently published a study about QSAR of platinum complexes with achiral ligands and (RR)-DACH [75] . Despite these examples, this theoretical approach fails with compounds (16a), (16b) and (16c) for which the opposite results were obtained, pointing out an intervention of other biological factors in stereoselective pharmacokinetics [40, 41] . Another outstanding evidence of the influence of other bionucleophiles than DNA has been given by Bernhardt et al. on complex 19c stereoisomers [45] . They clearly demonstrated in the case of both enantiomers of this compound that various preincubation times of the drug with the culture medium strongly modified the activity profile of each enantiomer. So, the stereoselective cytotoxicity could be « revealed » after a long incubation time or using buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis. They concluded that reactions with components of the cell culture medium took place before the complexes could bind to DNA. Other interactions between platinum complexes and biological elements are conceivable, disrupting classical relations between structure and cytotoxic activity. For example, some ligands have been designed to interact with transport proteins, which could be involved in penetration of complexes into the cells or which bind to a specific receptor [76] [77] [78] . Furthermore, complexes have been prepared involving ligands known for their anticancer activity [79] . For instance platinum complexes, displaying a diphenylethanediamine ligand have shown activity in breast cancer cells. Diphenylethanediamine has a three-dimensional structure relatively close to that of diethylstilboestrol and derivatives, which has an oestrogenic activity and, therefore, a supplementary antiproliferative effect on a hormone dependant cancer cell line could be demonstrated [80] .
Despite these well identified mechanisms, some aspects of stereoselectivity remain unclear and unexplained. This remark is almost exclusively related to the modification of the activity order when small structural changes are induced in the ligands (aromatic substituents, chain ramification,...). Although these experimental results do not give reasonable explanations, a logic answer might be found by taking into account interactions between the entire complex and other biological molecules than DNA. This conclusion is supported by the fact that small changes (see entries 11 and 12) in the structure, even at a significant distance of the platinum atom, caused inversion of the activity order in an enantiomeric series. Consequently, biomolecules being responsible for enantiomer differentiation have still to be unambiguously identified. 
OTHER FACTORS THAN DNA LEADING TO STEREO-SELECTIVE CYTOTOXICITY OF PLATINUM(II) ANTI-CANCER COMPLEXES WITH CHIRAL DIAMINE LIGANDS
In part 2, it has already been mentioned that platinum(II) complexes especially in the activated form are able to react with all kinds of (bio)nucleophiles present in body fluids. Many of them are very abundant in both extra-and intracellular media and are devoted to transportation, protection and metabolic purposes. In particular sulfur-containing bionucleophiles (thiols or thioethers in amino acids, peptides and proteins) are equipped with a specific binding tendency towards heavy metals like platinum. But also nitrogen atoms and carboxylic acid groups show a high preference to coordinate to the platinum(II) center. Since the first studies on the mechanism of action of anticancer platinum complexes research has also focused on the interaction of platinum with biologically relevant nucleophiles. In this context mainly cysteine, methionine, glutathione and albumine were involved in these studies. Nevertheless, the importance of such species with respect to the anticancer properties or the pharmacokinetics of the platinum-based coordination compounds is still unclear and under debate. Two scenario are feasible: (i) such species are produced from the organism for the reason of detoxification (endogenous cytoprotective products) or (ii) they are further involved in the anticancer process (storage hypothesis) to a minor extend. Some of these biological compounds are listed in Table 3 . Since nearly all of these bionucleophiles are per se chiral, it is logical to expect that, just like with DNA, a platinum complex with an optically pure chiral ligand could interact differently with these bionucleophiles resulting in diastereoisomeric adducts with unequal affinity. Logically, stereoselection could also arise from that kind of interaction. Scheme (4). Binding phases of platinum(II) complexes to DNA involved into stereoselectivity in cytotoxic activity. Important data have been collected with stereoisomers of oxaliplatin and derivatives with other leaving groups (3). The authors have obtained particularly intriguing results: i. the order of activity is dependent on the type of cancer cell line [14, 15] , ii. cis-3 is more easily taken up by the cells although it is the less active isomer [100] , iii. the leaving group influences the order of activity [25] and iv. trans-SS-3 binds DNA at a lower level than cis-3 (although trans-SS-3 is more active than cis-RS-3) [100] . In conclusion to the experiments, some precious explanations have been given in relation with other biomolecules than DNA but without experimental demonstration. On the other hand, differences in cellular accumulation have been found with both diastereoisomers of 19a, leading the authors to the conclusion that a stereoselective transport could transfer the respective isomer with unequal rates [101] . Since diastereoisomers have different physical properties and since simple diffusion through the phospholipid bilayer is esteemed as the major penetration pathway into the cell, different solubilities of rac-and meso-19a into the cell membrane might account for this phenomenon. Finally, it is noteworthy that several authors draw attention to interactions with bionucleophiles or unidentified biological components when unexpected results have been obtained [41, 45, 46, 48, 49, 53, 63] .
The mechanisms by which biological substances could affect chiral platinum complexes pharmacokinetics in a stereoselective way are summarized in scheme 5. Each of them may endow one stereoisomer with stereoselectivity in several phases, i.e. distribution, sequestration by proteins, binding to targets and elimination. The different interactions involved may, of course, act on one or several steps, leading to a particular pharmacological profile for these potential anticancer drugs. Among all these elements, only very few have been studied or, even, simply suspected to explain results inconsistent with theoretically expected activity. This hypothesis could be applied to the case of compound 15, exposed by Morikawa and coworkers, in which S-15 is the most cytotoxic one but unfortunately also the most nephrotoxic, owing to a higher accumulation in the kidneys [39] . This might be caused by extensive transport via the organic cation transporter localized in the kidneys. Another good example is the stereoselective peripheral neurotoxicity observed with compounds 3 and 8 which may arise from a yet unidentified biological system [102] . In entries 1 to 3 blood proteins are listed which react easily with cisplatin and, to a lesser extent, with oxaliplatin, decreasing in this way the amount of biologically active platinum complex. It is important to note that albumin is also present in the in vitro cytotoxicity test when using foetal calf serum.
Scheme (5) . Summary of possible interactions between chiral platinum complexes with biological compounds. The case illustrated here is a stereoselection favouring the cytotoxicity of the S enantiomer and endowing with toxicity and resistance to R enantiomer. Interactions occurring preferably with R or S enantiomers are annotated respectively by *R and *S.
In entries 4 and 5 proteins localized in cell membrane are mentioned, being involved into complex influx (CTR1) or efflux (MRPs). The mechanism by which CTR1 captures cisplatin has been recently studied. It involves cysteine-and methionine-rich regions of the channel binding the complex with a high efficiency [103] . Some proteins found in kidney cells are able to transform platinum complexes into nephrotoxic compounds (entry 6) or concentrate them in the renal cells cytoplasm (entry 7). When the complexes enter the cell, they may be detoxified by some compounds (entries 8, 11 and 12) . The real role of glutathione in cancer resistance remains controversial since some works clearly demonstrate that it participates to this phenomenon [104, 105] while others fail to prove it [106] . After reaction with DNA, NER and HMG proteins interact with injured zones of the DNA, leading either to repair (NER) or apoptosis (entries 9 and 10). These DNA associated proteins are well identified and their interactions with platinum complexes binding zones have been extensively studied with cisplatin. In the case of oxaliplatin (3), Faivre and coworkers have brought important contributions to the understanding of relations between binding of the complex and HMG/NER action. They analyzed interactions between oxaliplatin DNA adducts and these proteins [107] . They came to the conclusion that the hydrophobic DACH ligand could interact directly with proteins, showing in this way that differences in DNA bending are not the only factors leading to different activities between cisplatin and oxaliplatin. Since amino acids are present in all human fluids, they are supposed to have some affinity for platinum complexes. Particularly, cysteine and methionine, containing respectively a thiol or thioether, are of high interest. These amino-acids react with platinum complexes and take part into their pharmacokinetics (entries 13 and 14). The extent of such interactions and their impact on the anticancer activity or detoxification of platinum anticancer drugs is yet unknown. Finally, it can be also mentioned that some other proteins may interact with platinum complexes and, by this way, take part to their cytotoxic mechanism of action or in resistance of the cancer cell lines to the complexes. Among these proteins, heat shock protein 90 (Hsp90) [108] , telomerase [109] [110] [111] and survivin [112] have been identified but their precise role and their importance in the cytotoxic process has still to be determined. 5 
. ANALYTICAL TECHNIQUES AS BASIS FOR THE DRUG DEVELOPMENT PROCESS
As a consequence of the above-mentioned observations, interactions of bionucleophiles with platinum complexes are very important to be investigated during the development of new platinum anticancer drugs. The major pharmacological feature of chiral platinum complexes is that one stereoisomer may have excellent cytotoxic properties, while the other may be dangerous or have lower efficacy. Therefore, to optimize the design of novel platinum complexes with tumour inhibiting properties, it is essential to detect or to anticipate negative effects of bionucleophiles as soon as possible in the development process. Protection against nucleophilic attack can be achieved by using molecular modelling techniques to generate a shield effect around the platinum atom. This protection due to the steric hindrance of the ligand has been put forward to explain the lower reactivity of compound (19a) towards reactive biological compounds [113] . However, it has to be kept in mind that avoiding these undesirable reactions could also result in a negative effect on binding to DNA, leading to less active complexes. With the aim of overcoming these problems, a series of analytical techniques is available and extensively used in order to enhance our understanding of the mechanism of action of platinum-based drugs, thereby optimizing structure activity relationships and predicting the biological behaviour of novel drug candidates. The most widely applied methods in this field of research are listed in Table 4 and will briefly be mentioned. As far as biological efficiency is needed to design new drugs, emphasis has to be lain on methods which yield results in an acceptable time, with high throughput, and under standardized conditions. Among these analytical techniques (of course besides the biological evaluation), nuclear magnetic resonance (NMR), high-performance liquid chromatography (HPLC) and, probably with an increasing importance in the future, capillary electrophoresis (CE), are the most widely used analytical techniques for platinum drug development. The advantage of NMR is that experiments can be carried out directly in the NMR tube with a large variety of bionucleophiles or other nucleophiles in partly deuterated aqueous solution in order to mimic physiological conditions as much as possible. Major problems consist of the variation in acquisition times needed for the different nuclei which are short for 1 H, intermediate for 195 Pt and long for 13 C and 15 N. A major drawback is in some cases also the relatively high concentration needed for the NMR experiment. So, if the reaction speed is high, only 1 H-NMR can be used. Experiments may also be carried out with 15 Nenriched complexes using two-dimensional HMQC NMR techniques, providing information about the coordination sphere around the platinum center. Finally, another important point to note is that NMR allows, at the same time, structural analysis and quantification of the species formed during the reaction course. One problem is associated with the accuracy in comparison with other methods. Therefore, chromatographic techniques are very useful tools, particularly when hyphenated methods such as LC-NMR and LC-MS are utilized. These systems are especially efficient since they have a high resolution power and consequently all reaction products can be separated and identified. In this context, a highly promising method is capillary electrophoresis (CE) as well as CE-MS. One of the most important advantages of CE is that interactions between platinum complexes and bionucleophiles can be measured directly in aqueous solution under physiologically relevant conditions, allowing to determine the time-dependent binding of platinum complexes to all biologically occurring nucleophiles.
CONCLUSIONS
Platinum complexes still remain the only metal-based drugs in anticancer therapy and, as it has been noted with oxaliplatin, chiral complexes may, like other chiral drugs, lead to stereoselective activity or pharmacokinetics. However, it has to be recognized that the stereoselection, which has been extensively studied, was almost exclusively explained in terms of diastereoselective interactions with DNA. Although this approach has been supported by many experimental proofs and also by biological test results, the remarkably high reactivity of platinum complexes towards compounds, other than the targeted DNA, must be taken into account for a complete analysis of the pharmacokinetics. The predominant number of relevant bionucleophiles taking part in distribution and metabolism of platinum complexes has been identified. Therefore one eminent point within the drug development process is to focus on the above mentioned interactions before/or in conjunction with the evaluation of the biological activity. Indeed, these nucleophiles will be the first to react before the complexes reach DNA and, therefore, may induce resistance and side effects. The interest in chiral platinum complexes is logically the result of different interactions with bionucleophiles leading in last consequence to improved anticancer activity and maybe to less undesirable side effects. The best practice for a rational design of new chiral cytotoxic platinum complexes is therefore to systematically evaluate their behavior towards bionucleophiles at a very early stage during drug development in order to reduce development time and costs. 
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